Literature DB >> 32891040

The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation.

Inge Mannaerts1, Nathalie Eysackers2, Elise Anne van Os3, Stefaan Verhulst4, Tiffany Roosens5, Ayla Smout6, Andreas Hierlemann7, Olivier Frey8, Sofia Batista Leite9, Leo A van Grunsven10.   

Abstract

A major obstacle in the development of efficient therapies for progressive liver fibrosis is the lack of representative in vitro models of liver fibrosis to aid in understanding the mechanisms of the disease and to promote the development of pharmaceuticals. Our aim was to develop a relevant in vitro mouse liver fibrosis model, based on the central hypothesis that liver fibrosis in vitro cannot be studied using only hepatic stellate cells (HSCs)-the main producer of scar tissue during fibrosis-, but requires cultures in which at least hepatocytes are integrated. We established robust methods to generate co-culture spheroids from freshly isolated mouse hepatocytes and HSCs. Characteristics and functionality of these spheroids were analyzed by qPCR of cell-type specific markers, CYP induction and immunohistochemistry. Compound toxicity was determined by ATP-assays. Hepatocytes and HSCs maintained their cell-type specific marker expression over a 15-day culture period without major hepatocyte dedifferentiation or HSC activation. Exposure of spheroids to TGFβ can directly activate HSCs, while acetaminophen exposure mounts a hepatocyte damage dependent activation of HSCs. Pharmaceuticals with known anti-fibrotic properties, such as Valproic acid and Verteporfin, reduce HSC activation in response to hepatocyte damage in these cultures. A comparison between the fibrotic response of the spheroid co-cultures and in vivo activated HSCs showed that these 3D co-cultures are more representative than the commonly used 2D HSC monocultures. Finally, we showed that the 3D cultures can be integrated in microfluidic chips. We conclude that our hepatocyte-stellate cell-spheroid cultures are a robust in vitro model of liver fibrosis. This model could be used to further unravel the mechanism of HSC activation and facilitate the discovery of, or testing for novel anti-fibrotic compounds, as these spheroids better reproduce HSC in vivo activation compared to the more traditional 2D mono-culture models.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acetaminophen; Bioreactor; Hepatocytes; Liver fibrosis; Liver spheroids; Stellate cells

Mesh:

Year:  2020        PMID: 32891040     DOI: 10.1016/j.biomaterials.2020.120335

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  5 in total

Review 1.  A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies.

Authors:  Ana S Serras; Joana S Rodrigues; Madalena Cipriano; Armanda V Rodrigues; Nuno G Oliveira; Joana P Miranda
Journal:  Front Cell Dev Biol       Date:  2021-02-22

Review 2.  Stem cell therapy and tissue engineering strategies using cell aggregates and decellularized scaffolds for the rescue of liver failure.

Authors:  Jiabin Zhang; Hon Fai Chan; Haixia Wang; Dan Shao; Yu Tao; Mingqiang Li
Journal:  J Tissue Eng       Date:  2021-02-01       Impact factor: 7.813

Review 3.  Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery.

Authors:  Tine Tricot; Catherine M Verfaillie; Manoj Kumar
Journal:  Cells       Date:  2022-01-27       Impact factor: 6.600

4.  MicroRNA-223 Suppresses Human Hepatic Stellate Cell Activation Partly via Regulating the Actin Cytoskeleton and Alleviates Fibrosis in Organoid Models of Liver Injury.

Authors:  Chaiyaboot Ariyachet; Nattaya Chuaypen; Pornchai Kaewsapsak; Naphat Chantaravisoot; Depicha Jindatip; Saranyapin Potikanond; Pisit Tangkijvanich
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

5.  The utility of biomedical scaffolds laden with spheroids in various tissue engineering applications.

Authors:  SooJung Chae; Jiyoung Hong; Hanjun Hwangbo; GeunHyung Kim
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.